QT:{{”
“The authors count the number of citations for each Nobel
prize-winner, using a service provided by JSTOR, a digital library. They look at what happens to Nobel prize-winners before and after they win their prizes. The data span from 1930 to 2005. One of the problems facing the authors was that, in 2005, there were many more JSTOR articles than in 1930. Therefore, raw citation numbers were
standardised by the total number of articles published in that year. The authors call the standardised units “Arrows”, after Kenneth Arrow, the economist who won the prize in 1972.”
“}}

QT:{{”
““We don’t believe that the data we are collecting is any kind of realistic peer review, but it does tell us something about the types of papers people find interesting and what leads them to be
suspicious,” Leek says. “Ultimately we hope to correlate this data with information about where the papers are published, retractions, and other more in-depth measurements of paper quality and interest.”

But don’t take Papr too seriously, because its developers don’t. “This app is provided solely for entertainment of the scientific community and may be taken down at any time with no notice because Jeff gets tired of it,” the Papr website says.”
“}}

QT:{{”
“goal is part of a broader set of recommendations in support of open science, a concept that also includes improved storage of and access to research data. The Dutch government, which currently holds the rotating E.U. presidency, had lobbied hard for Europe-wide support for open science, as had Carlos Moedas, the European commissioner for research and innovation.
….
We probably don’t realize it yet, but what the Dutch presidency has achieved is just unique and huge,” Moedas said
“}}

QT:{{"In a recently published letter to Nature Biotechnology, Lixia Yao,
IGSB core faculty Andrey Rzhetsky and colleagues dissect the decisions
made in funding choices. His team compares these choices by funding
agencies to trades in a financial market. In this communication, they
expand on the idea that there exists an imbalance between health needs
and biomedical research investment.

In order to fairly examine the relationship between biomedical need
and biomedical research, they validated a new, insurance based measure
of health burden that enables automatic evaluation of burden and
research investment for many more diseases than have been previously
assessed. "
"}}